Search stocks

Find any stock by ticker or company name

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

О нас

Контакты

[email protected]

Мы в соцсетях

Instagram
Telegram
LinkedIn

Все права защищены.

Условия использования

Главная
Избранное
Рынки
Скринер
Новости
О нас

RNTX - Rein Therapeutics Inc. Последние новости | Finranks

Home

/

RNTX

R

Rein Therapeutics Inc. (RNTX)

NCM – Цена в реальном времени. Валюта: USD

1.12

-0.03 (-2.61%)

При закрытии: May 12, 2026, 4:00 PM EDT

1.12

0.00 (0.00%)

После закрытия: May 12, 2026, 6:00 PM EDT

Обзор
Новости
График
Финансы
Дивиденды
Прогноз
Владельцы
Профиль

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on or about May 4, 2026, subject to the satisfaction of customary closing conditions. The offering consisted entirely of common stock with no warrants.

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near term Enrollment initiated in March 2026, with patients being added on a regular basis Clinical trial sites active in the United States, Australia, and Poland, with additional countries expected to open in the near term AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF). The Company has enrolled 8 patients in its RENEW trial to date, with 2 additional patients expected to be enrolled this week.

Why Is Rein Therapeutics Stock Trading Higher On Monday?

Why Is Rein Therapeutics Stock Trading Higher On Monday?

Rein Therapeutics (NASDAQ:RNTX) stock is trading higher on Monday, with a session volume of 41.2 million compared to its average volume of 162.67 thousand, according to data from Benzinga Pro.

Видео

No Data

There is no data to display

Пресс-релизы

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

Rein Therapeutics Announces Pricing of $50 Million Underwritten Public Offering of Common Stock

AUSTIN, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics, Inc. ("Rein" or the "Company") (NASDAQ: RNTX), a clinical-stage biopharmaceutical company advancing a novel pipeline of first-in-class medicines for orphan pulmonary and fibrosis indications, today announced the pricing of its underwritten public offering of fifty million shares of its common stock at a public offering price of $1.00 per share for aggregate gross proceeds of $50 million, prior to deducting underwriting discounts and commissions and other offering expenses. In addition, the Company has granted the underwriters a 45-day option to purchase up to an additional 7.5M shares of common stock at the public offering price per share, less the underwriting discounts and commissions, to cover over-allotments, if any. The offering is expected to close on or about May 4, 2026, subject to the satisfaction of customary closing conditions. The offering consisted entirely of common stock with no warrants.

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Rein Therapeutics Provides Clinical Trial Update for Phase 2 RENEW Study of LTI-03 in Idiopathic Pulmonary Fibrosis

Patient enrollment accelerates across expanding number of clinical trial sites in multiple countries 8 patients enrolled, with additional patients expected in the near term Enrollment initiated in March 2026, with patients being added on a regular basis Clinical trial sites active in the United States, Australia, and Poland, with additional countries expected to open in the near term AUSTIN, Texas, April 29, 2026 (GLOBE NEWSWIRE) -- Rein Therapeutics ("Rein") (NASDAQ: RNTX), a biopharmaceutical company advancing a novel pipeline of first-in-class medicines to address significant unmet medical needs in orphan pulmonary and fibrosis indications, today provided an update on its ongoing Phase 2 RENEW clinical trial evaluating LTI-03 for the treatment of idiopathic pulmonary fibrosis (IPF). The Company has enrolled 8 patients in its RENEW trial to date, with 2 additional patients expected to be enrolled this week.